Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endometrial Polyps: Pathophysiology and Clinical Consequences

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00247923
Recruitment Status : Completed
First Posted : November 2, 2005
Last Update Posted : July 6, 2011
Sponsor:
Information provided by:
Oslo University Hospital

Brief Summary:
The aim of these studies is to study the natural history, the symptoms of, as well as the effect of hysteroscopic resection of endometrial polyps. Furthermore, another aim is to study new diagnostic techniques to differentiate between malignant and benign endometrial polyps.

Condition or disease Intervention/treatment Phase
Endometrial Polyp Endometrial Cancer Procedure: Hysteroscopic resection of endometrial polyps. (TCRP) Not Applicable

Detailed Description:

Study Part 1: New diagnostic methods for the prediction of malignancy in endometrial polyps: A prospective pilot study.

Study of angiogenesis by identification of specific angiogenesis factors in tissue biopsies from the endometrium and by Doppler ultrasound combined with IV contrast. We hope to find specific characteristics with new vessel formation in the endometrial polyp, which can play a role in the prognostic evaluation regarding the risk for cancer development. We will compare women with endometrial polyps and women with endometrial cancer to see if these methods of angiogenesis evaluation may be useful in separating benign polyps from premalignant and malignant polyps.

Study Part 2: The natural history of endometrial polyps. A prospective randomised study of patients with endometrial polyps.

Blood loss during menstruation is documented with the help of a standardized form (PBAC). The patients are randomized to hysteroscopic resection of the endometrial polyp or 6 months of observation. A new registration of blood loss during menstruation is performed by patients in both groups. In the intervention group, a new gynaecological examination 6 months after the resection documents the presence of residual polyp or symptoms. The other group is examined again after 6 months of observation. Symptoms and findings with the second examination are compared with symptoms and findings at the first examination, any changes are documented and the final outcome in the to groups are compared.

Study Part 3: The occurrence and natural history of asymptomatic endometrial polyps in perimenopausal women. A prospective controlled study.

Registration of blood loss during menstruation is documented with the help of a standardized form (PBAC) and gynaecological examination including SIS of 1000 randomly selected women in the age group 45-50. Where endometrial polyps are identified, we document the size and number of polyps and an endometrial biopsy is taken. After including a woman with an endometrial polyp in the study, the next woman without endometrial polyp is recruited to the control group. After one year, blood loss during menstruation is registered again, and all women with endometrial polyps as well as the control group have a new examination including vaginal ultrasound, SIS and endometrial biopsy. Symptoms and findings are compared with symptoms and findings at the first examination and all changes are documented. If the woman has a persistent endometrial polyp when examined at 1 year, she is offered treatment with hysteroscopic polyp resection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1186 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Endometrial Polyps. Pathophysiology and Clinical Consequences.
Study Start Date : October 2005
Actual Study Completion Date : February 2009



Primary Outcome Measures :
  1. Study part 1. Angiogenesis factor levels in endometrial biopsies in patients with endometrial polyps compared to patients with endometrial cancer
  2. Resistance in the feeding vessel measured by doppler examination combined with intravenous (i.v.) contrast in patients with endometrial polyps and endometrial cancer
  3. Study part 2. Change in pictorial blood loss assessment chart (PBAC) score in intervention compared to observation group
  4. Study part 3. Change in PBAC score in women with endometrial polyps compared to control group

Secondary Outcome Measures :
  1. Associated factors for the development of endometrial polyps
  2. Change in endometrial polyp size and symptoms after 6 and 12 months of observation


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 90 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Study 1:

    • Endometrial polyp (EP) group: Presence of endometrial polyp verified by vaginal ultrasound examination.
    • Cancer group: Presence of endometrial cancer verified by histological examination.
  • Study 2:

    • Pre- or perimenopausal women.
    • Presence of endometrial polyp verified by vaginal ultrasound.
  • Study 3:

    • EP group: Presence of endometrial polyp verified by vaginal ultrasound.
    • Control group: Normal endometrium by vaginal ultrasound examination.

Exclusion Criteria:

  • Study 1: Earlier severe allergic reactions.
  • Study 2:

    • Postmenopausal patient.
    • Pregnancy.
    • Additional condition requiring treatment detected during examination. Malignancy or atypical hyperplasia detected by histological examination.
  • Study 3:

    • Previous hysterectomy.
    • Pregnancy.
    • Additional condition requiring treatment detected during examination. Malignancy or atypical hyperplasia detected by histological examination.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00247923


Locations
Layout table for location information
Norway
Gynaecologial department, Ullevaal University Hospital
Oslo, Norway, 0407
Sponsors and Collaborators
Ullevaal University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Olav Istre, MD., PhD. Department og Gynaecology, Ullevaal University Hospital, Oslo, Norway.

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00247923    
Other Study ID Numbers: PP I/II/III
22200205
First Posted: November 2, 2005    Key Record Dates
Last Update Posted: July 6, 2011
Last Verified: February 2009
Keywords provided by Oslo University Hospital:
Endometrial polyps.
Angiogenesis.
Asymptomatic.
Symptoms.
Malignancy.
Treatment efficiency.
Vaginal bleeding.
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Uterine Neoplasms
Polyps
Pathological Conditions, Anatomical
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female